KDM5A and neuroendocrine carcinoma: Further studies in larger cohorts are needed to determine to what extent KDM5A- or IFNB1 combinations are NEC- or NET G3 specific and further efforts are needed to delineate the exact mechanisms behind treatment susceptibilities.